Gastric, or Gastroesophageal Junction AdenocarcinomaPhase 3NCT03777657
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
A Phase 3 study testing Tislelizumab, Cisplatin and Oxaliplatin in people with Gastric, or Gastroesophageal Junction Adenocarcinoma, run by BeiGene at 149 sites in 13 countries.
Trial summary
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric, or Gastroesophageal Junction Adenocarcinoma
- What is being tested?
- Tislelizumab, Cisplatin and Oxaliplatin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 997 participants
- Where
- 149 sitesin 13 countries
- Study dates
- 13 Dec 2018to 27 Aug 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Locally advanced unresectable or metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed adenocarcinoma
- No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer. NOTE: Participants may have received prior neoadjuvant or adjuvant therapy as long as it was completed and have no recurrence or disease progression for at least 6 months.
- Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 within 7 days prior to randomization
- Adequate organ function ≤ 7 days prior to randomization
Who cannot join
- Has squamous cell or undifferentiated or other histological type GC
- Active leptomeningeal disease or uncontrolled brain metastasis
- Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
- Prior therapy with an anti-programmed cell death protein-1 (PD-1), anti-programmed cell death protein ligand-1 (PD-L1), anti-programmed cell death protein ligand-2 (PD-L2), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
149 sites in 13 countries.
149 sites in 13 countries
China51 sites
Peking University Third Hospital
Beijing, Beijing Municipality, 100000
Beijing Chao Yang Hospital
Beijing, Beijing Municipality, 100020
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730
Chinese Pla General Hospital
Beijing, Beijing Municipality, 100853
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality, 101149
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004
The First Hospital of Jilin University
Changchun, Jilin, 130021
Xiangya Hospital of Central South University
Changsha, Hunan, 410008
Hunan Cancer Hospital
Changsha, Hunan, 410013
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, 400042
Foshan First Peoples Hospital
Foshan, Guangdong, 528000
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005
Fujian Cancer Hospital
Fuzhou, Fujian, 350014
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510080
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, 541001
Hainan General Hospital
Haikou, Hainan, 570206
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003
Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, 310009
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
Hefei, Anhui, 230088
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230601
Shandong Cancer Hospital
Jinan, Shandong, 250117
Yunnan Cancer Hospital
Kunming, Yunnan, 650100
The First Hospital of Lanzhou University
Lanzhou, Gansu, 730000
Linyi Cancer Hospital
Linyi, Shandong, 276001
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008
Nantong Tumor Hospital Branch South
Nantong, Jiangsu, 226000
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, 266000
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200092
The First Hospital of China Medical University
Shenyang, Liaoning, 110001
The General Hospital of Shenyang Military
Shenyang, Liaoning, 110016
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042
Shenzhen Peoples Hospital
Shenzhen, Guangdong, 518020
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022
Hubei Cancer Hospital
Wuhan, Hubei, 430079
Henan Cancer Hospital
Zhengzhou, Henan, 450000
Henan Provincial Peoples Hospital
Zhengzhou, Henan, 450003
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052
Japan23 sites
Johas Kansai Rosai Hospital
Amagasakishi, Hyōgo, 660-8511
Chiba Cancer Center
Chiba, Chiba, 260-8717
National Cancer Center Hospital
Chuoku, Tokyo, 104-0045
Tokyo Metropolitan Tama Medical Center
Fuchushi, Tokyo, 183-8524
Nho Kyushu Cancer Center
Fukuoka, Fukuoka, 811-1395
Hamamatsu University School of Medicine, University Hospital
Hamamatsushi, Shizuoka, 431-3192
Saitama Medical University International Medical Center
Hidakashi, Saitama, 350-1298
Izumi City General Hospital
Izumishi, Osaka, 594-0073
Tesshokai Kameda General Hospital
Kamogawashi, Chiba, 296-8602
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, 920-8530
Saitama Cancer Center
Kitaadachigun, Saitama, 362-0806
Kagawa University Hospital
Kitagun, Kagawa-ken, 761-0793
Cancer Institute Hospital of Jfcr
Kotoku, Tokyo, 135-8550
Kurashiki Central Hospital
Kurashikishi, Okayama-ken, 710-8602
Nho Shikoku Cancer Center
Matsuyama, Ehime, 791-0280
Okayama University Hospital
Okayama, Okayama-ken, 700-8558
Nho Osaka National Hospital
Osakashi, Osaka, 540-0006
Gunma Prefectural Cancer Center
Otashi, Gunma, 373-8550
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648
Center Hospital of the National Center For Global Health and Medicine
Shinjukuku, Tokyo, 162-8655
Osaka University Hospital
Suitashi, Osaka, 565-0871
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515
Oita University Hospital
Yufushi, Oita Prefecture, 879-5593
Spain13 sites
Hospital Clinic de Barcelona
Barcelona, 8036
Hospital de Basurto
Bilbao, 48013
Hospital General Universitario de Elche
Elche, 3203
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Hospital Universitario La Paz
Madrid, 28046
Hospital Universitario Hm Madrid Sanchinarro
Madrid, 28050
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222
Hospital Regional Universitario de Malaga
Málaga, 29010
Complejo Hospitalario de Navarra
Pamplona, 31008
Hospital Universitario Virgen Del Rocio
Seville, 41013
Hospital Clinico Universitario de Valencia
Valencia, 46010
Initia Oncologia, Slp
Valencia, 46010
Hospital Universitario Miguel Servet
Zaragoza, 50009
Italy11 sites
Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi
Bologna, 40138
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, 20133
Istituto Nazionale Tumori Fondazione G Pascale
Naples, 80131
Iov Istituto Oncologico Veneto Irccs
Padova, 35128
Ao Ospedali Riuniti Marche Nord
Pesaro, 61122
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Roma, 133
Irccs Ospedale Casa Sollievo Della Sofferenza
San Giovanni Rotondo, 71013
Aou Senese Policlinico Santa Maria Alle Scotte
Siena, 53100
Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino
Torino, 10126
Azienda Ospedaliera Universitaria Delle Marche
Torrette, 60020
Russia10 sites
Arkhangelsk Regional Clinical Oncological Dispensary
Arkhangelsk, Arkhangelskaya oblast, 163045
Rbih Ivanovo Regional Oncological Dispensary
Ivanovo, Ivanovo Oblast, 153040
Vitamed Llc
Moscow, Moscow, 121309
Sbhi of Novosibirsk Region Novosibirsk Regional Oncological Dispensary
Novosibirsk, Novosibirsk Oblast, 630108
Bih of Omsk Region Clinical Oncology Dispensary
Omsk, Omsk Oblast, 644013
Pavlov First Saint Petersburg State Medical University
SaintPetersburg, Sankt-Peterburg, 197022
Private Educational Institution of Higher Education Medical University Reaviz
Samara, Samaraskaya Oblast', 443011
Fsbi Clinical Research and Practical Center For Specialized Medical Care (Oncology)
SanktPetersburg, Sankt-Peterburg, 197758
State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary
Volgograd, Volgograd Oblast, 400138
Sbih of Yaroslavl Region Regional Clinical Oncological Hospital
Yaroslavl, Yaroslavl Oblast, 150054
South Korea10 sites
Kyungpook National University Chilgok Hospital
Daegu, Gyeongsangbukdo, 41404
National Cancer Center
Goyang-si, Gyeonggi-do, 10408
Chonnam National University Hwasun Hospital
HwasunGun, Jeollanam-do, 58128
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080
Severance Hospital Yonsei University Health System
Seoul, Seoul Teugbyeolsi, 03722
Asan Medical Center
Seoul, Seoul Teugbyeolsi, 05505
Chung Ang University Hospital
Seoul, Seoul Teugbyeolsi, 6973
The Catholic University of Korea, St Vincents Hospital
Suwon, Gyeonggi-do, 16247
Ajou University Hospital
Suwon, Gyeonggi-do, 16499
Turkey (Türkiye)8 sites
Acibadem Adana Hospital
Adana, 01130
Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
Ankara, 06620
Nonu Universitesi Tip Fakultesi
Battalgazi, 44280
Dicle University Medical Faculty
Diyarbakır, 21080
Akdeniz University Hospital
Konyaalt, 07070
Iu C, Clinical Research Excellence Application and Research Center
Stanbul, 34098
Namik Kemal University
Tekirdağ, 59100
Karadeniz Tecnical Uni Med Fac
Trabzon, 61080
France7 sites
Centre Georges Francois Leclerc
Dijon, 21079
Chu Besancon Hopital Jean Minjoz
Doubs, 25030
Hopital de La Timone
Marseille, 13005
Icl Alexis Vautrin
Meurthe Et Moselle, 54519
Hopital Nord Franche Comte Site Du Mittan
Montbéliard, 25200
Centre Antoine Lacassagne
Nice, 06100
Chu Bordeaux Hopital Haut Leveque
Pessac, 33600
United States6 sites
Ohio State University Hospital
Columbus, Ohio, 43210
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee, 37203
Southeastern Regional Medical Center
Newnan, Georgia, 30265
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
University of California Davis Health System
Sacramento, California, 95817
Reading Hospital
West Reading, Pennsylvania, 19611
Poland4 sites
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-952
Centrum Terapii Wspolczesnej Jm Jasnorzewska Sp Komandytowo Akcyjna
Lodz, 90-242
Przychodnia Med Polonia Sp Z Oo
Poznan, 60-693
Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy
Warsaw, 02-034
Taiwan3 sites
Kaohsiung Medical University Chung Ho Memorial Hospital
Kaohsiung City, 807
National Cheng Kung University Hospital
Tainan, 704
Taipei Veterans General Hospital
Taipei, 11217
United Kingdom2 sites
Velindre Cancer Centre
Cardiff, CF14 2TL
Sarah Cannon Research Institute Uk
London, W1G 6AD
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Being tested
- Tislelizumab, Placebo, Cisplatin, Oxaliplatin, Capecitabine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TislelizumabDrug
Also called BGB-A317, TEVIMBRA®
200 mg intravenously (IV) on Day 1 of each 21-day cycle
PlaceboDrug
Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
CisplatinDrug
80 mg/m² IV on Day 1 of each 21-day cycle
OxaliplatinDrug
130 mg/m² IV on Day 1 of each 21-day cycle
CapecitabineDrug
1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
5-FluorouracilDrug
800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle
| Study group | Role | What they receive |
|---|---|---|
| Tislelizumab + Chemotherapy | Experimental | Participants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-fluorouracil (5-FU) on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity. Receives: Drug: Tislelizumab; Drug: Cisplatin; Drug: Oxaliplatin; Drug: Capecitabine; Drug: 5-Fluorouracil |
| Placebo + Chemotherapy | Placebo comparator | Participants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-FU on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity. Receives: Drug: Placebo; Drug: Cisplatin; Drug: Oxaliplatin; Drug: Capecitabine; Drug: 5-Fluorouracil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival in PD-L1 Positive Participants
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Measured: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.
Overall Survival in the Intent-to-Treat (ITT) Analysis Set
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Measured: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Secondary outcomes (17)
Progression-free Survival (PFS) in PD-L1 Positive Participants
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first.
Median PFS was estimated using the Kaplan-Meier method.
Measured: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in PD-L1 Positive Participants
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator.
Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Progression-free Survival (PFS) in the ITT Analysis Set
Progression-free survival is defined as the time from the date of randomization to the date of the first objectively documented tumor progression assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first.
Median PFS was estimated using the Kaplan-Meier method.
Measured: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in the ITT Analysis Set
ORR is defined as the percentage of participants whose best overall response is complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors v1.1 assessed by the investigator.
Investigators conducted assessments of radiological tumor response by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response (DOR) in PD-L1 Positive Participants
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first.
Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response in the ITT Analysis Set
DOR is defined as the time from the first determination of an objective response assessed by the investigator per RECIST v1.1, until the first documentation of progression or death, whichever occurred first.
Progressive disease (PD): At least a 20% increase in the size of target lesions, taking as reference the smallest size on study, with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or any new lesions.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
Measured: Baseline and Cycles 4 and 6
Change From Baseline in EORTC QLQ-C30 Fatigue Score
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.
Measured: Baseline and Cycles 4 and 6
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)
EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales: Dysphagia/odynophagia (4 items), Pain/discomfort (3 items), Dietary restrictions (5 items), Upper gastro-intestinal (GI) symptoms (3 items), Specific emotional problems (3 items) and 4 single items. Each question is answered on a scale from 0 (Not at all) to 4 (Very Much), where lower scores indicate fewer symptoms/better QoL.
Raw scores were transformed to a scale from 0 to 100, where lower scores indicate better QoL.
The QLQ-STO22 Index score is the mean of the 6 domain scores and 4 single items.
Measured: Baseline and Cycles 4 and 6
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Measured: Baseline and Cycles 4 and 6
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not.
An SAE is any untoward medical occurrence that, at any dose met any of the following criteria:
- Resulted in death
- Was life-threatening
- Required hospitalization or prolongation of existing hospitalization
- Resulted in disability/incapacity
- Was a congenital anomaly/birth defect
- Was considered a significant medical AE by the Investigator based on medical judgement.
Measured: From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.
Disease Control Rate in PD-L1 Positive Participants
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator and the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Disease Control Rate in the ITT Analysis Set
Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the investigator per RECIST v1.1. Investigators conducted assessments of radiological tumor response by CT or MRI per RECIST version 1.1 about every six weeks during the first 48 weeks of the study and every nine weeks thereafter.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
SD: Neither sufficient shrinkage in size of lesions to qualify for PR nor sufficient increase to qualify for PD, and no new lesions.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in PD-L1 Positive Participants
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Durable SD: Stable disease for ≥ 24 weeks.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in the ITT Analysis Set
Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the Investigator per RECIST v1.1.
CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must have reduction in short axis to < 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
Durable SD: Stable disease for ≥ 24 weeks.
Measured: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in PD-L1 Positive Participants
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
Measured: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in the ITT Analysis Set
Time to response is defined as the time from randomization to the first determination of an objective response per RECIST version 1.1 as assessed by the investigator.
Measured: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2018
- Study start13 Dec 2018
- Primary completion28 Feb 2023
- Study completion27 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Gastric, or Gastroesophageal Junction AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by BeiGeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 997 participants (actual)
Sponsor and investigators
- Lead sponsor
- BeiGene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jin Wang, MD, Study director, BeiGene
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03777657
- Sponsor's protocol ID
- BGB-A317-305
- Other IDs
- 2018-000312-24, CTR20181841, JapicCTI-194799, 2018
- Status last verified
- Jan 2025
- First submitted
- 9 Nov 2018
- Last updated
- 14 Feb 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Moehler M, Correa MC, Oh DY, Xu RH, Kato K, Barzi A, Barnes FB, Xu Y, Sheng T, Barnes G, Victor T. Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score >/= 5%: results from the RATIONALE-305 trial. Qual Life Res. 2026 Oct 25;35(11):314. doi: 10.1007/s11136-026-04416-4.
PubMed 42927580Rha SY, Ryu MH, Kim JG, Xu S, Xu Y, Lee KW. Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. Curr Med Res Opin. 2026 May;42(5):1031-1041. doi: 10.1080/03007995.2026.2686048. Epub 2026 Jun 29.
PubMed 42371751Kato K, Xu RH, Oh DY, Bai Y, Shi J, Lee KW, Hirano H, Xu H, Sheng T, B Barnes F, Barnes G. Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study. Curr Med Res Opin. 2026 Apr;42(4):809-819. doi: 10.1080/03007995.2026.2682010. Epub 2026 Jun 9.
PubMed 42262249Qiu MZ, Lee KW, Mohler M, Luo HY, Hirano H, Zhang T, Wang FH, Ba Y, Rha SY, Wang F, He MM, Xu S, Pan X, Xu RH. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. EClinicalMedicine. 2026 May 15;95:103980. doi: 10.1016/j.eclinm.2026.103980. eCollection 2026 May.
PubMed 42205142Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Gracian A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M. Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Adv Ther. 2026 Jan;43(1):165-183. doi: 10.1007/s12325-025-03415-0. Epub 2025 Nov 18.
PubMed 41251890Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin. 2025 Jun;41(6):1007-1016. doi: 10.1080/03007995.2025.2501588. Epub 2025 Jun 18.
PubMed 40528576Moehler M, Yoon HH, Wagner DC, Yang S, Shi J, Zhang Y, Hu H, La Placa C, Peng Y, Du W, McCampbell A, Xu W, Shen Z, Xu H, Huang R, Kato K. Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab. Mod Pathol. 2025 Sep;38(9):100793. doi: 10.1016/j.modpat.2025.100793. Epub 2025 May 13.
PubMed 40373876Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression >/= 1%: A Retrospective Analysis of RATIONALE-305. Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13.
PubMed 40075025Li W, Wan L, Zhang J. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective. Expert Rev Gastroenterol Hepatol. 2024 Jun;18(6):293-301. doi: 10.1080/17474124.2024.2373730. Epub 2024 Jun 28.
PubMed 38923910Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876.
PubMed 38806195
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- ClinicalTrials.gov ID
- NCT03777657
- Acronym / sponsor ID
- BGB-A317-305
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 997 participants (actual)
- Lead sponsor
- BeiGeneIndustry (pharma, biotech, devices)
- Study start
- 13 Dec 2018 (actual)
- Primary completion
- 28 Feb 2023 (actual)
- Study completion
- 27 Aug 2024 (actual)
- First posted
- 17 Dec 2018 (actual)
- Results
- Posted 14 Feb 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tislelizumab + Chemotherapy | Experimental | Drug: Tislelizumab, Drug: Cisplatin, Drug: Oxaliplatin, Drug: Capecitabine, Drug: 5-FluorouracilParticipants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-fluorouracil (5-FU) on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity. |
| Placebo + Chemotherapy | Placebo comparator | Drug: Placebo, Drug: Cisplatin, Drug: Oxaliplatin, Drug: Capecitabine, Drug: 5-FluorouracilParticipants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Chemotherapy consisted of 1000 mg/m² capecitabine twice daily on Days 1-14 and 130 mg/m² oxaliplatin on Day 1, or 800 mg/m² 5-FU on Days 1-5 and 80 mg/m² cisplatin on Day 1 of each 21-day cycle. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Locally advanced unresectable or metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed adenocarcinoma
- No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer. NOTE: Participants may have received prior neoadjuvant or adjuvant therapy as long as it was completed and have no recurrence or disease progression for at least 6 months.
- Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 within 7 days prior to randomization
- Adequate organ function ≤ 7 days prior to randomization
Key exclusion criteria (5 listed)
- Has squamous cell or undifferentiated or other histological type GC
- Active leptomeningeal disease or uncontrolled brain metastasis
- Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
- Prior therapy with an anti-programmed cell death protein-1 (PD-1), anti-programmed cell death protein ligand-1 (PD-L1), anti-programmed cell death protein ligand-2 (PD-L2), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TislelizumabAlso: BGB-A317, TEVIMBRA®200 mg intravenously (IV) on Day 1 of each 21-day cycle | Drug | Tislelizumab + Chemotherapy |
| PlaceboPlacebo to match tislelizumab IV on Day 1 of each 21-day cycle | Drug | Placebo + Chemotherapy |
| Cisplatin80 mg/m² IV on Day 1 of each 21-day cycle | Drug | Placebo + Chemotherapy, Tislelizumab + Chemotherapy |
| Oxaliplatin130 mg/m² IV on Day 1 of each 21-day cycle | Drug | Placebo + Chemotherapy, Tislelizumab + Chemotherapy |
| Capecitabine1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle | Drug | Placebo + Chemotherapy, Tislelizumab + Chemotherapy |
| 5-Fluorouracil800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle | Drug | Placebo + Chemotherapy, Tislelizumab + Chemotherapy |
Primary outcome
Overall Survival in PD-L1 Positive Participants
Time frame: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Overall Survival in the Intent-to-Treat (ITT) Analysis Set
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
17 secondary outcomes
Progression-free Survival (PFS) in PD-L1 Positive Participants
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in PD-L1 Positive Participants
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Progression-free Survival (PFS) in the ITT Analysis Set
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Overall Response Rate (ORR) in the ITT Analysis Set
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response (DOR) in PD-L1 Positive Participants
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Duration of Response in the ITT Analysis Set
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in EORTC QLQ-C30 Fatigue Score
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Gastric Cancer Module QLQ-STO22 (EORTC QLQ-STO22)
Time frame: Baseline and Cycles 4 and 6
Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
Time frame: Baseline and Cycles 4 and 6
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug to 30 days after last dose or the initiation of a new anticancer therapy, whichever occurred first, up to the end of study; maximum treatment duration was 59.3 months in Tislelizumab and 56.8 months in the Placebo group.
Disease Control Rate in PD-L1 Positive Participants
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Disease Control Rate in the ITT Analysis Set
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in PD-L1 Positive Participants
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Clinical Benefit Rate (CBR) in the ITT Analysis Set
Time frame: Response was assessed every 6 weeks for the first 48 weeks and every 9 weeks thereafter; up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in PD-L1 Positive Participants
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Time to Response (TTR) in the ITT Analysis Set
Time frame: From randomization up to the final efficacy analysis data cut-off date of 28 February 2023; Median (range) time on follow-up was 13.2 (0.1 - 50.1) months.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42927580Moehler M, Correa MC, Oh DY, Xu RH, Kato K, Barzi A, Barnes FB, Xu Y, Sheng T, Barnes G, Victor T. Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score >/= 5%: results from the RATIONALE-305 trial. Qual Life Res. 2026 Oct 25;35(11):314. doi: 10.1007/s11136-026-04416-4.
- Derived from this study: PubMed 42371751Rha SY, Ryu MH, Kim JG, Xu S, Xu Y, Lee KW. Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. Curr Med Res Opin. 2026 May;42(5):1031-1041. doi: 10.1080/03007995.2026.2686048. Epub 2026 Jun 29.
- Derived from this study: PubMed 42262249Kato K, Xu RH, Oh DY, Bai Y, Shi J, Lee KW, Hirano H, Xu H, Sheng T, B Barnes F, Barnes G. Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study. Curr Med Res Opin. 2026 Apr;42(4):809-819. doi: 10.1080/03007995.2026.2682010. Epub 2026 Jun 9.
- Derived from this study: PubMed 42205142Qiu MZ, Lee KW, Mohler M, Luo HY, Hirano H, Zhang T, Wang FH, Ba Y, Rha SY, Wang F, He MM, Xu S, Pan X, Xu RH. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. EClinicalMedicine. 2026 May 15;95:103980. doi: 10.1016/j.eclinm.2026.103980. eCollection 2026 May.
- Derived from this study: PubMed 41251890Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Gracian A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M. Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Adv Ther. 2026 Jan;43(1):165-183. doi: 10.1007/s12325-025-03415-0. Epub 2025 Nov 18.
- Derived from this study: PubMed 40528576Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin. 2025 Jun;41(6):1007-1016. doi: 10.1080/03007995.2025.2501588. Epub 2025 Jun 18.
- Derived from this study: PubMed 40373876Moehler M, Yoon HH, Wagner DC, Yang S, Shi J, Zhang Y, Hu H, La Placa C, Peng Y, Du W, McCampbell A, Xu W, Shen Z, Xu H, Huang R, Kato K. Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab. Mod Pathol. 2025 Sep;38(9):100793. doi: 10.1016/j.modpat.2025.100793. Epub 2025 May 13.
- Derived from this study: PubMed 40075025Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression >/= 1%: A Retrospective Analysis of RATIONALE-305. Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13.
- Derived from this study: PubMed 38923910Li W, Wan L, Zhang J. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective. Expert Rev Gastroenterol Hepatol. 2024 Jun;18(6):293-301. doi: 10.1080/17474124.2024.2373730. Epub 2024 Jun 28.
- Derived from this study: PubMed 38806195Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876.
- Individual participant dataSharing planned: Yes
Related trials for Gastric, or Gastroesophageal Junction Adenocarcinoma
RecruitingPhase 2
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Active, not recruitingPhase 2
Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal Adenocarcinoma
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
RecruitingPhase 2
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Stomach Neoplasms
RecruitingPhase 1/2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
RecruitingPhase 2/3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jin Wang, MD study director
BeiGene
149 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tislelizumab, Cisplatin and Oxaliplatin in people with Gastric, or Gastroesophageal Junction Adenocarcinoma, run by BeiGene at 149 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 149 sites in China, Japan, Spain, Italy, Russia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Feb 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival in PD-L1 Positive Participants (time frame: From randomization up to the primary analysis data cut-off date of 8 October 2021; Median (range) time on follow-up was 11.8 (0.1 - 33.4) months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03777657, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2025.